Asenapine vs Quetiapine (Seroquel)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Asenapine
Marketed by AbbVie and partners
NCT00212784 · Phase 3 · completed
This 52-week trial randomly assigned 1,225 people with schizophrenia to asenapine or to olanzapine, with participants, carers, investigators and outcome assessors all unaware of assignment. The primary measure was change in total PANSS symptom score. Asenapine improved symptoms by 21.0 points against 27.5 points for olanzapine, a difference favouring olanzapine at p<0.0001, so asenapine was less effective than its active comparator on this measure.
Reported efficacy
Change in total PANSS score at endpoint (Screening, Week 76, 100, and once every 24 weeks thereafter until endpoint): Mean PANSS total score changes during first year of treatment were - 37.0 asenapine and - 35.3 olanzapine, with further changes of 1.6 asenapine and - 0.8 olanzapine at the extension study endpoint (unclear)
Result source: NCT00212771
Quetiapine (Seroquel)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT00305422 · Phase 3 · completed
The study was randomized and double-blinded with an active risperidone comparator, but its small sample of 45 participants limits the strength of the evidence. The primary comparison was not reported, and the primary focus included cognitive and functional brain-activation measures rather than a clearly specified hard clinical endpoint.
Next expected readout: February 2032 · NCT07152184 (registry estimate)
Reported efficacy
Clinical efficacy of both neuroleptics, especially with regard to cognitive deficits and functional brain activation between baseline and week 12: Global cognition improved vs baseline at week 12 on quetiapine (p<0.01) and risperidone (p<0.05).
Result source: NCT00305422
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Asenapine | Quetiapine (Seroquel) |
|---|---|---|
| PANSS total, change | -21.7 vs -16.2−5.5 vs placeboNCT0161718718 other results
| -24 vs -15.9−8.1 vs placeboNCT018103801 other result
|
| CGI-S, change | -1.2 vs -1−0.2 vs placeboNCT0161718717 other results
| -1.4 vs -0.9−0.5 vs placeboNCT018103801 other result
|
| PANSS response | 39.3% vs 20.7%+18.6 vs placeboNCT010981101 other result
| 62.7% vs 32.1%+30.6 vs placeboNCT01810380 |
| PSP, change | —Not posted · NCT00212771 | 15.3 vs 9.4+5.9 vs placeboNCT01810380 |
| Relapse (% of patients) | —Not posted · NCT00212771 | —Not posted · NCT00305422 |
PANSS total, change
- Asenapine
- -21.7 vs -16.2−5.5 vs placeboNCT01617187
18 other results
- -12.2 vs -0.9 NCT01098110
- -25.5 vs -17.8 NCT01190254
- -14.2 vs -0.9 NCT01098110
- -17.4 vs -16.2 NCT01617187
- -23.7 vs -17.8 NCT01190254
- -19 vs -15.4 NCT01617187
- -17.1 vs -15.5 NCT01617187
- -14.8 vs -13.2 NCT01617187
- -12.5 vs -10.7 NCT01617187
- -9.1 vs -7.1 NCT01617187
- -4.9 vs -4.8 NCT01617187
- -17 vs -15.4 NCT01617187
- -12.3 vs -15.5 NCT01617187
- -12 vs -13.2 NCT01617187
- -9.9 vs -10.7 NCT01617187
- -7.2 vs -7.1 NCT01617187
- -4 vs -4.8 NCT01617187
- -21 vs -27.5 NCT00212784
- Quetiapine (Seroquel)
- -24 vs -15.9−8.1 vs placeboNCT01810380
1 other result
- -33.4 vs -35.9 NCT00882518
CGI-S, change
- Asenapine
- -1.2 vs -1−0.2 vs placeboNCT01617187
17 other results
- -0.7 vs -0.2 NCT01098110
- -1.1 vs -0.8 NCT01617187
- -0.9 vs -0.8 NCT01617187
- -1.3 vs -0.8 NCT01190254
- -0.8 vs -0.7 NCT01617187
- -0.6 vs -0.5 NCT01617187
- -0.3 vs -0.3 NCT01617187
- -0.2 vs -0.2 NCT01617187
- -0.8 vs -0.2 NCT01098110
- -0.9 vs -1 NCT01617187
- -0.9 vs -0.8 NCT01617187
- -0.7 vs -0.8 NCT01617187
- -1.1 vs -0.8 NCT01190254
- -0.6 vs -0.7 NCT01617187
- -0.6 vs -0.5 NCT01617187
- -0.3 vs -0.3 NCT01617187
- -0.1 vs -0.2 NCT01617187
- Quetiapine (Seroquel)
- -1.4 vs -0.9−0.5 vs placeboNCT01810380
1 other result
- -1.8 vs -2.1 NCT00882518
PANSS response
- Asenapine
- 39.3% vs 20.7%+18.6 vs placeboNCT01098110
1 other result
- 43.8% vs 20.7% NCT01098110
- Quetiapine (Seroquel)
- 62.7% vs 32.1%+30.6 vs placeboNCT01810380
PSP, change
- Asenapine
- —Not posted · NCT00212771
- Quetiapine (Seroquel)
- 15.3 vs 9.4+5.9 vs placeboNCT01810380
Relapse (% of patients)
- Asenapine
- —Not posted · NCT00212771
- Quetiapine (Seroquel)
- —Not posted · NCT00305422
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
11 other shared endpoints and safety
Coverage. Asenapine: 15 of 15 rows · Quetiapine (Seroquel): 15 of 15 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Asenapine Rows use multiple source trials | Quetiapine (Seroquel) Rows use multiple source trials |
|---|---|---|
| CGI-I responder rate · % of participants | 66.7% (n=111) vs 62.6% (n=99) placebo @ 6wk5 mg BIDa,b,c NCT01617187 · Phase 3 · registry result, not featured evidence show 1 more dose59.4% (n=96) vs 62.6% (n=99) placebo @ 6wk2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence | 87.6% (n=194) vs 88.9% (n=190) Chlorpromazine @ 6wkb,c NCT00882518 · Phase 3 · registry result, not featured evidence |
| CGI-I absolute value · score | 2.5 vs 3.1 placebo score @ 8wk5.0 mg BIDa,b,c,d NCT01190254 · Phase 3 · registry result, not featured evidence show 1 more dose2.8 vs 3.1 placebo score @ 8wk2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence | 2.5 vs 3 placebo score @ 6wkb,c,d NCT01810380 · Phase 3 · registry result, not featured evidence |
| PANSS 30% responder rate · % of participants | 25.2% (n=111) vs 19.2% (n=99) placebo @ 6wk5 mg BIDa,b,c NCT01617187 · Phase 3 · registry result, not featured evidence show 1 more dose14.6% (n=96) vs 19.2% (n=99) placebo @ 6wk2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence | 57.7% (n=194) vs 66.3% (n=190) Chlorpromazine @ 6wkb,c NCT00882518 · Phase 3 · registry result, not featured evidence |
| PANSS General Psychopathology absolute change · score | -10.1 vs -8 placebo score @ 6wk5 mg BIDa,b,c NCT01617187 · Phase 3 · registry result, not featured evidence show 1 more dose-8.9 vs -8 placebo score @ 6wk2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence | -11.6 vs -8.2 placebo score @ 6wkb,c NCT01810380 · Phase 3 · registry result, not featured evidence 1 other source trial-12.9 vs -13.9 Chlorpromazine score @ 6wk NCT00882518 · Phase 3 · registry result, not featured evidence |
| PANSS Marder Anxiety Depression absolute change · score | -3.4 vs -3 placebo score @ 6wk5 mg BIDa,b,c NCT01617187 · Phase 3 · registry result, not featured evidence show 1 more dose-2.9 vs -3 placebo score @ 6wk2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence | -3.6 vs -2.9 placebo score @ 6wkb,c NCT01810380 · Phase 3 · registry result, not featured evidence |
| PANSS Marder Disorganized Thought absolute change · score | -4.3 vs -2.7 placebo score @ 6wk5 mg BIDa,b,c NCT01617187 · Phase 3 · registry result, not featured evidence show 1 more dose-3.8 vs -2.7 placebo score @ 6wk2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence | -4.8 vs -3.2 placebo score @ 6wkb,c NCT01810380 · Phase 3 · registry result, not featured evidence |
| PANSS Marder Negative absolute change · score | -4.7 vs -4 placebo score @ 6wk5 mg BIDa,b,c NCT01617187 · Phase 3 · registry result, not featured evidence show 1 more dose-3.4 vs -4 placebo score @ 6wk2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence | -4.8 vs -3.6 placebo score @ 6wkb,c NCT01810380 · Phase 3 · registry result, not featured evidence |
| PANSS Marder Positive absolute change · score | -7.6 vs -6.2 placebo score @ 6wk5 mg BIDa,b,c NCT01617187 · Phase 3 · registry result, not featured evidence show 1 more dose-6.8 vs -6.2 placebo score @ 6wk2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence | -8.4 vs -5.7 placebo score @ 6wkb,c NCT01810380 · Phase 3 · registry result, not featured evidence |
| PANSS Marder Uncontrolled Hostility/Excitement absolute change · score | -1.8 vs -1.1 placebo score @ 6wk5 mg BIDa,b,c NCT01617187 · Phase 3 · registry result, not featured evidence show 1 more dose-1.1 vs -1.1 placebo score @ 6wk2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence | -2.8 vs -1.8 placebo score @ 6wkb,c NCT01810380 · Phase 3 · registry result, not featured evidence |
| PANSS Negative Subscale absolute change · score | -4.9 vs -3.4 placebo score @ 8wk5.0 mg BIDa,b,c,d NCT01190254 · Phase 3 · registry result, not featured evidence show 1 more dose-4.8 vs -3.4 placebo score @ 8wk2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence | -4.5 vs -3.1 placebo score @ 6wkb,c,d NCT01810380 · Phase 3 · registry result, not featured evidence 1 other source trial-5.9 vs -6.7 Chlorpromazine score @ 6wk NCT00882518 · Phase 3 · registry result, not featured evidence |
| PANSS Positive Subscale absolute change · score | -9.1 vs -6 placebo score @ 8wk5.0 mg BIDa,b,c,d NCT01190254 · Phase 3 · registry result, not featured evidence show 1 more dose-7.9 vs -6 placebo score @ 8wk2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence | -8.1 vs -5.4 placebo score @ 6wkb,c,d NCT01810380 · Phase 3 · registry result, not featured evidence 1 other source trial-9.9 vs -11.1 Chlorpromazine score @ 6wk NCT00882518 · Phase 3 · registry result, not featured evidence |
| Dropout rate | 44.4%5 mg twice dailye NCT01549041 · Phase 4 · registry result, not featured evidence show 23 more results16.7%10 mg daily in the evening NCT01549041 · Phase 4 · registry result, not featured evidence 54.8%5/10 mg BID NCT01142596 · Phase 3 · registry result, not featured evidence 0%5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 1%2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 49.7% NCT01244828 · Phase 3 · registry result, not featured evidence 35.2%5 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 40.1%10 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 50%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 20.9%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 20.8%5.0 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 17.3%2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 33.7% NCT00174265 · Phase 3 · registry result, not featured evidence 50.4% NCT00145496 · Phase 3 · registry result, not featured evidence 30.4% NCT00150176 · Phase 3 · registry result, not featured evidence 15.7% NCT00265343 · Phase 3 · registry result, not featured evidence 67.7% NCT00156065 · Phase 3 · registry result, not featured evidence 0%5 mg NCT01206517 · Phase 1 · registry result, not featured evidence 33.3%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 25%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%2.5 mg NCT01206517 · Phase 1 · registry result, not featured evidence | —Seroquel IRe NCT01213836 · Phase 4 · registry result, not featured evidence show 7 more results—Seroquel XR NCT01213836 · Phase 4 · registry result, not featured evidence 30.4% NCT00156715 · Phase 4 · registry result, not featured evidence —Quetiapine NCT01810380 · Phase 3 · registry result, not featured evidence 20.8%Quetiapine Extended Release NCT01810380 · Phase 3 · registry result, not featured evidence 19.4% NCT00882518 · Phase 3 · registry result, not featured evidence 37.8% NCT00227305 · Phase 3 · registry result, not featured evidence 16.7% NCT00642369 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | 22.2%5 mg twice dailye NCT01549041 · Phase 4 · registry result, not featured evidence show 23 more results0%10 mg daily in the evening NCT01549041 · Phase 4 · registry result, not featured evidence 22.3%5/10 mg BID NCT01142596 · Phase 3 · registry result, not featured evidence 0%5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 0%2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 23.6% NCT01244828 · Phase 3 · registry result, not featured evidence 17%5 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 17.6%10 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 0%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 5.1%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 7.5%5.0 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 6.1%2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 8.1% NCT00174265 · Phase 3 · registry result, not featured evidence 17.2% NCT00145496 · Phase 3 · registry result, not featured evidence 8.2% NCT00150176 · Phase 3 · registry result, not featured evidence 7.5% NCT00265343 · Phase 3 · registry result, not featured evidence 11.8% NCT00156065 · Phase 3 · registry result, not featured evidence —5 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —2.5 mg NCT01206517 · Phase 1 · registry result, not featured evidence | —Seroquel IRe NCT01213836 · Phase 4 · registry result, not featured evidence show 7 more results—Seroquel XR NCT01213836 · Phase 4 · registry result, not featured evidence — NCT00156715 · Phase 4 · registry result, not featured evidence —Quetiapine NCT01810380 · Phase 3 · registry result, not featured evidence 2.6%Quetiapine Extended Release NCT01810380 · Phase 3 · registry result, not featured evidence 4.6% NCT00882518 · Phase 3 · registry result, not featured evidence 10.5% NCT00227305 · Phase 3 · registry result, not featured evidence 6.7% NCT00642369 · Phase na · registry result, not featured evidence |
| Serious AEs | 0%5 mg twice dailye NCT01549041 · Phase 4 · registry result, not featured evidence show 23 more results0%10 mg daily in the evening NCT01549041 · Phase 4 · registry result, not featured evidence 20.4%5/10 mg BID NCT01142596 · Phase 3 · registry result, not featured evidence 4.4%5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 5.2%2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 8.9% NCT01244828 · Phase 3 · registry result, not featured evidence 5.7%5 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 2.8%10 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 12.5%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 3.6%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 2.8%5.0 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 3.1%2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 4.7% NCT00174265 · Phase 3 · registry result, not featured evidence 12.3% NCT00145496 · Phase 3 · registry result, not featured evidence 3.1% NCT00150176 · Phase 3 · registry result, not featured evidence 6.7% NCT00265343 · Phase 3 · registry result, not featured evidence 14.1% NCT00156065 · Phase 3 · registry result, not featured evidence 0%5 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%2.5 mg NCT01206517 · Phase 1 · registry result, not featured evidence | 0%Seroquel IRe NCT01213836 · Phase 4 · registry result, not featured evidence show 7 more results0%Seroquel XR NCT01213836 · Phase 4 · registry result, not featured evidence 18.8% NCT00156715 · Phase 4 · registry result, not featured evidence 1.3%Quetiapine NCT01810380 · Phase 3 · registry result, not featured evidence —Quetiapine Extended Release NCT01810380 · Phase 3 · registry result, not featured evidence 0% NCT00882518 · Phase 3 · registry result, not featured evidence 12.1% NCT00227305 · Phase 3 · registry result, not featured evidence 0% NCT00642369 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | 5 mg twice dailye daytime drowsiness 22.2% NCT01549041 · Phase 4 · registry result, not featured evidence show 19 more results10 mg daily in the evening daytime drowsiness 0% NCT01549041 · Phase 4 · registry result, not featured evidence 5/10 mg BID nasopharyngitis 21.7% schizophrenia 10.8% somnolence 10.8% NCT01142596 · Phase 3 · registry result, not featured evidence 5 mg BID insomnia 15% (placebo 13.9%) headache 8.8% (placebo 2%) anxiety 7.1% (placebo 11.9%) NCT01617187 · Phase 3 · registry result, not featured evidence 2.5 mg BID headache 10.3% (placebo 2%) insomnia 9.3% (placebo 13.9%) anxiety 7.2% (placebo 11.9%) NCT01617187 · Phase 3 · registry result, not featured evidence nasopharyngitis 21% somnolence 12.7% weight increased 12.7% NCT01244828 · Phase 3 · registry result, not featured evidence 5 mg BID akathisia 11.4% (placebo 5.2%) hypoaesthesia oral 10.9% (placebo 3.4%) insomnia 9.7% (placebo 12.1%) NCT01098110 · Phase 3 · registry result, not featured evidence 10 mg BID schizophrenia 13.8% (placebo 24.1%) somnolence 12.2% (placebo 1.7%) akathisia 10.5% (placebo 5.2%) NCT01098110 · Phase 3 · registry result, not featured evidence accidental overdose 12.5% acne 12.5% akathisia 12.5% NCT01190267 · Phase 3 · registry result, not featured evidence somnolence 14.8% headache 6.6% sedation 5.1% NCT01190267 · Phase 3 · registry result, not featured evidence 5.0 mg BID somnolence 17% (placebo 6.9%) sedation 11.3% (placebo 2%) insomnia 9.4% (placebo 5.9%) NCT01190254 · Phase 3 · registry result, not featured evidence 2.5 mg BID somnolence 20.4% (placebo 6.9%) dizziness 7.1% (placebo 1%) headache 7.1% (placebo 5.9%) NCT01190254 · Phase 3 · registry result, not featured evidence insomnia 10.6% weight increased 5.9% headache 2.4% NCT00174265 · Phase 3 · registry result, not featured evidence insomnia 17.6% somnolence 14.8% headache 13.5% NCT00145496 · Phase 3 · registry result, not featured evidence insomnia 20.1% (placebo 24.5%) somnolence 16% (placebo 17.2%) weight increased 14.4% (placebo 10.9%) NCT00150176 · Phase 3 · registry result, not featured evidence headache 5.2% influenza 5.2% schizophrenia 5.2% NCT00265343 · Phase 3 · registry result, not featured evidence insomnia 18.5% headache 10.9% parkinsonism 10.9% NCT00156065 · Phase 3 · registry result, not featured evidence 5 mg dystonia 66.7% dizziness 33.3% nausea 33.3% NCT01206517 · Phase 1 · registry result, not featured evidence 10 mg hypoaesthesia oral 50% dizziness 38.9% dysgeusia 38.9% NCT01206517 · Phase 1 · registry result, not featured evidence 2.5 mg sedation 33.3% dysgeusia 16.7% hypoaesthesia oral 16.7% NCT01206517 · Phase 1 · registry result, not featured evidence | e somnolence 3.2% delusion 1.6% dizziness 1.6% NCT01213836 · Phase 4 · registry result, not featured evidence show 5 more resultspsychotic disorder 1.6% sedation 1.6% sleep disorder 1.6% NCT01213836 · Phase 4 · registry result, not featured evidence dry mouth 43.8% sedation 43.8% increased appetite/weight gain 31.3% NCT00156715 · Phase 4 · registry result, not featured evidence somnolence 22.2% (placebo 5%) weight increased 13.1% (placebo 3.7%) dizziness 11.8% (placebo 0.6%) NCT01810380 · Phase 3 · registry result, not featured evidence constipation 25% dizziness 14.3% insomnia 12.8% NCT00882518 · Phase 3 · registry result, not featured evidence somnolence 30.3% increased appetite 20% sedation 18.9% NCT00227305 · Phase 3 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 8 weeks versus 6 weeks.
- ePopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Asenapine
show 1 more result
show 1 more result
show 2 more results
show 15 more results
show 15 more results
show 1 more result
show 1 more result
+ 20 further endpoints in the CSV export.
Quetiapine (Seroquel)
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Asenapine's landscape · Quetiapine (Seroquel)'s landscape